Lilly's tirzepatide outperformed placebo in resolving MASH, and over 50% of patients showed fibrosis improvement after 52 weeks.

EASL Conclusion Session Emphasized Novel Clinical Data on Unique HBV-targeted TCR T Cell Therapy (SCG101) Demonstrating Enhanced Survival Rates in HBV-linked Liver Cancer.

Geron Receives FDA Approval for RYTELO™ (imetelstat), a Novel Telomerase Inhibitor, to Treat Transfusion-Dependent Anemia in Adults with Lower-Risk MDS.

Annexon Reports Preliminary Success in Phase 3 Trial of Novel C1q Inhibitor ANX005 for Guillain-Barré Syndrome.

Quell Therapeutics progresses QEL-001, their innovative CAR-Treg cell therapy, to the efficacy phase of the LIBERATE Phase 1/2 trial in liver transplant recipients.

Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.

Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.

AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.

Jun 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Amgen announces successful phase 3 trial results for Uplizna® (inebilizumab-cdon) in treating immunoglobulin G4-related disease (IgG4-RD).

Boston Pharmaceuticals Unveils Data at EASL Congress 2024 Demonstrating BOS-580, a Long-acting FGF21 Analogue, Enhances Lipid Profiles in Phenotypic MASH Patients.

Nutcracker Therapeutics Showcases Improved Efficacy of B Cell Lymphoma Drug Candidate NTX-472 at 2024 ASCO Meeting.